Madrigal Shares Tumble as Quarterly Losses Exceed Forecasts

Revenue Growth vs. Bottom-Line Pressure

The West Conshohocken-based biopharmaceutical firm posted a net loss of $58.6 million, or $2.57 per share, for the final quarter of the year. This result was considerably wider than the 90-cent loss per share projected by analysts, according to data from FactSet. The earnings miss comes despite a strong top-line performance, where revenue more than tripled to $321.1 million, surpassing the $312.5 million consensus estimate.

Investors reacted sharply to the wider deficit, sending the stock down to $450.06 during late morning trading. Despite the immediate volatility, Madrigal’s broader market position remains robust, with the stock maintaining a 31% gain over the past 12 months. The current sell-off reflects heightened investor sensitivity to the company's spending levels as it navigates its current commercialization and development phase.

The sharp increase in revenue indicates significant operational progress, yet the higher-than-expected costs highlight the capital-intensive nature of the late-stage biotech sector. According to the report, the company continues to manage the transition from a research-focused entity to a commercial player, a shift that often entails unpredictable quarterly expenditures.